[Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer].

Afshar-Oromieh, A.; Alberts, I.; Sachpekidis, C.; Rominger, A. (2019). [Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer]. Der Urologe, 58(12), pp. 1429-1434. Springer 10.1007/s00120-019-01067-x

[img] Text
RomA_Prostataspezifische Membranantigen(PSMA)-basierte Diagnostik und Therapie des Prostatakarzinoms.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (2MB) | Request a copy

BACKGROUND Since their clinical introduction in 2011, PSMA-PET/CT (PSMA: prostate-specific membrane antigen) as well as PSMA therapy of prostate cancer (PC) have spread rapidly worldwide. OBJECTIVES To summarize the current knowledge about both PSMA-PET/CT and PSMA therapy of PC. METHODS The knowledge derived from the literature as well as the authors' experiences were collected in this review. RESULTS PSMA-PET/CT demonstrates a very high sensitivity and specificity for the detection of recurrent PC as well as for the primary staging of intermediate- and high-risk PC. PSMA therapy shows promising results in third-line treatment for patients with castration-resistant, metastatic PC. CONCLUSIONS PSMA-PET/CT is meanwhile established as the gold standard for the detection of recurrent PC and is in the process of assuming the same role for primary staging of intermediate- to high-risk PC. PSMA therapy serves as a promising third-line therapy in an increasing number of centers.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Afshar Oromieh, Ali; Alberts, Ian Leigh; Sachpekidis, Christos and Rominger, Axel Oliver

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1433-0563

Publisher:

Springer

Language:

German

Submitter:

Sabine Lanz

Date Deposited:

23 Jan 2020 14:24

Last Modified:

23 Jan 2020 14:24

Publisher DOI:

10.1007/s00120-019-01067-x

PubMed ID:

31705143

Uncontrolled Keywords:

PET/CT Radioligand Radiotherapy Recurrence Tumor marker

BORIS DOI:

10.7892/boris.137419

URI:

https://boris.unibe.ch/id/eprint/137419

Actions (login required)

Edit item Edit item
Provide Feedback